STOCK TITAN
  1. Home
  2. News
  3. ALLO

Allogene Therapeutics, Inc. - ALLO STOCK NEWS

Welcome to our dedicated page for Allogene Therapeutics news (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics stock.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies for cancer and autoimmune diseases. Leveraging the expertise of former Kite Pharma executives, Allogene aims to revolutionize cancer treatment with innovative off-the-shelf CAR T solutions. These therapies, derived from healthy donor cells, provide a scalable and readily available option, eliminating the lengthy and complex process of personalized cell therapy.

The company's portfolio includes 16 pre-clinical T cell therapy assets and UCART19, an allogeneic CAR T therapy in phase 1 development for acute lymphoblastic leukemia (ALL). Notable core programs target various malignancies such as lymphoma, leukemia, solid tumors, and autoimmune diseases. Among its leading investigational products is cemacabtagene ansegedleucel (cema-cel), currently undergoing pivotal phase 2 ALPHA3 trials for large B-cell lymphoma (LBCL) and phase 1 trials for relapsed/refractory chronic lymphocytic leukemia (CLL). ALLO-316, aimed at renal cell carcinoma (RCC), and ALLO-329, targeting autoimmune diseases with Dagger® technology, further strengthen Allogene's robust pipeline.

Allogene collaborates with leading biotech firms like Foresight Diagnostics and Arbor Biotechnologies to enhance its clinical development capabilities. Recent achievements include strategic partnerships and a $15 million grant from the California Institute for Regenerative Medicine (CIRM) supporting the development of ALLO-316. Financially, Allogene reported a strong cash runway extending into 2026, with latest funding rounds ensuring continued support for its R&D initiatives.

Stay informed on Allogene's progress as it drives the future of allogeneic CAR T therapy, providing broader patient access and more efficient cancer treatment options.

News

Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting

Rhea-AI Summary
Allogene Therapeutics presented preclinical data on their AlloCAR T product candidate targeting Claudin18.2-positive gastric and pancreatic tumors. The data showed potent activity in vitro and in vivo, suggesting the potential for clinical benefit with a single off-the-shelf infusion. ALLO-182, the lead candidate, is currently in the IND-enabling phase of development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.85%
Tags
clinical trial
-
News

Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting

Rhea-AI Summary
Allogene Therapeutics presented data on their Cloak and Dagger technologies at the SITC Annual Meeting. These technologies aim to enhance the performance of AlloCAR T cell candidates by reducing rejection by the immune system. The Cloak technology prevents recognition by host T cells, while the Dagger technology enables dual specificity against CD70-positive host immune cells and CD19-positive tumor cells. These advancements have the potential to make CAR T therapies more scalable and accessible to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.85%
Tags
clinical trial
-
News

Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update

Rhea-AI Summary
Allogene Therapeutics, Inc. provided a corporate update and reported financial results for Q3 2023. They ended the quarter with $497.7 million in cash, cash equivalents, and investments. The company expects a decrease in cash of approximately $230 million in 2023, with a cash runway projected into the second half of 2025. They announced preclinical posters to be presented at upcoming conferences, highlighting the potential of their AlloCAR T platform and providing updates on their clinical trials for ALLO-501A and ALLO-647. The company also announced appointments to its leadership team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.85%
Tags
earnings
News

Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology

Rhea-AI Summary
Allogene Therapeutics, Inc. will present two poster presentations at the 65th Annual Meeting of the American Society of Hematology (ASH). The first poster is a safety review of all 85 patients treated in the Phase 1 ALPHA/ALPHA2 studies in relapsed/refractory Large B Cell Lymphoma (LBCL) and follicular lymphoma (FL). The second poster showcases translational results from ALPHA2, comparing expansion kinetics among 11 allogeneic CAR T recipients. These presentations highlight the importance of lymphodepletion in allogeneic cell therapy and provide insights into improving CAR T expansion and efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.95%
Tags
none
-
News

Allogene Therapeutics Announces Participation in November Investor Conferences

Rhea-AI Summary
Allogene Therapeutics, Inc. will participate in two investor conferences in November. The first conference is TD Cowen's 7th Annual Fall Oncology Innovation Summit on November 3rd, and the second is Jefferies London Healthcare Conference on November 15th. Webcasts of the conferences will be available on the company's website, and replays will be accessible for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
none
-
News

Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023

Rhea-AI Summary
Allogene Therapeutics will report third quarter 2023 financial results on November 2, 2023, followed by a conference call and webcast at 2:00 PM PT/5:00 PM ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences earnings
News

Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Rhea-AI Summary
Allogene Therapeutics announces three preclinical poster presentations at the Society for Immunotherapy of Cancer Annual Meeting. The presentations will focus on next-generation AlloCAR T platform technologies and the ALLO-182 solid tumor product candidate. The work aims to enhance engraftment and expansion of AlloCAR T products, potentially improving their persistence and anti-tumor activity. This could expand the potential of off-the-shelf CAR T products and reduce the intensity of conditioning therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
none
-
News

Allogene Therapeutics Announces Participation in September Investor Conference

Rhea-AI Summary
Allogene Therapeutics to participate in Baird 2023 Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
none
-
News

Cantor Fitzgerald Bolsters Healthcare and Biotechnology Equity Research Team with Addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D.

Rhea-AI Summary
Cantor Fitzgerald announces the addition of two premier research analysts, Josh Schimmer and Eric Schmidt, to its Healthcare and Biotechnology Research platform. Cantor's goal is to become the premier full-service investment bank in Healthcare and Biotechnology. Schimmer and Schmidt express excitement about joining Cantor and their commitment to providing outstanding service in the biotechnology industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
none
News

Allogene Therapeutics Appoints Earl Douglas as General Counsel

Rhea-AI Summary
Allogene Therapeutics, Inc. (Nasdaq: ALLO) appoints Earl Douglas as General Counsel, bringing over 35 years of legal and compliance experience in biotech and medical device companies. Mr. Douglas will oversee all legal aspects and join the Leadership Team, supporting the company's goal of a BLA submission for ALLO-501A, its lead AlloCAR T™ product candidate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
management

FAQ

What is the current stock price of Allogene Therapeutics (ALLO)?

The current stock price of Allogene Therapeutics (ALLO) is $2.27 as of November 15, 2024.

What is the market cap of Allogene Therapeutics (ALLO)?

The market cap of Allogene Therapeutics (ALLO) is approximately 490.6M.

What is Allogene Therapeutics, Inc.?

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of allogeneic CAR T therapies for cancer and autoimmune diseases.

What are Allogene's core products?

Allogene's core products include UCART19, cemacabtagene ansegedleucel (cema-cel), ALLO-316 for renal cell carcinoma, and ALLO-329 for autoimmune diseases.

What is unique about Allogene's therapies?

Allogene's therapies are off-the-shelf CAR T products derived from healthy donor cells, providing scalable and readily available treatment options.

Who are Allogene's key partners?

Allogene collaborates with biotech firms like Foresight Diagnostics and Arbor Biotechnologies to enhance its clinical development capabilities.

In which clinical trials is cema-cel involved?

Cema-cel is involved in the pivotal phase 2 ALPHA3 trial for large B-cell lymphoma (LBCL) and phase 1 trials for relapsed/refractory chronic lymphocytic leukemia (CLL).

What recent financial achievement did Allogene secure?

Allogene received a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support the development of its ALLO-316 product.

How does Allogene's financial outlook appear?

Allogene reported a strong cash runway extending into 2026, bolstered by recent funding rounds to support continued research and development efforts.

What is the focus of Allogene's ALLO-316 trial?

The ALLO-316 trial focuses on advanced or metastatic renal cell carcinoma (RCC), assessing the safety, tolerability, and preliminary efficacy of the therapy.

What is the Dagger® technology used in ALLO-329?

Dagger® technology is used in ALLO-329 to eliminate the need for lymphodepletion while targeting CD19+ B-cells and CD70+ activated T-cells in autoimmune diseases.

What is the goal of Allogene's therapies?

Allogene aims to provide broadly accessible, scalable, and efficient cancer and autoimmune disease treatments through its pioneering allogeneic CAR T therapies.

Stock ALLO logo
Allogene Therapeutics, Inc.

Nasdaq:ALLO

ALLO Rankings

#3120 Ranked by Market Cap
N/A Ranked by Dividends

ALLO Stock Data

490.61M
209.67M
17.43%
79.91%
18.8%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SOUTH SAN FRANCISCO